Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VATICO: SARS-CoV-2 Vaccination Strategies in Recovered Patients
NCT04969250Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 6
01
Overview
Phase 4, randomised, open-label trial of elasomeran and tozinameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Ratio of 48-Week to Baseline Neutralizing Antibody Levels. Started Aug 2021; status: completed.
02
Drugs
elasomerantozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04969250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969250.